NU 578 Unit 4 Exam Prep Document | 2026/2027 Edition | 150
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NU 578 Unit 4 at the University of South Alabama
features 150 verified questions and answers, meticulously curated to align with the 2026/2027
academic curriculum. Designed to facilitate mastery of advanced nursing concepts, this resource
provides detailed rationales and evidence-based explanations for each question. Students can
confidently prepare for the exam with this A+ graded study aid, which covers all critical content areas
and reflects the latest practice standards.
Key Features:
Advanced Pathophysiology and Pharmacotherapeutics
Health Assessment and Diagnostic Reasoning
Evidence-Based Practice and Research Integration
Leadership and Interprofessional Collaboration
Ethical and Legal Considerations in Advanced Practice
Patient Safety and Quality Improvement
Updates for 2026:
- Updated to reflect 2026/2027 curriculum changes
- Incorporated latest evidence-based practice guidelines
- Revised rationales for enhanced clarity and depth
- Added new questions on emerging healthcare topics
- Aligned with current NCLEX and advanced practice standards
Abstract:
The NU 578 Unit 4 Exam Prep Document for the 2026/2027 academic year at the University of South Alabama
offers a rigorous and comprehensive review of advanced nursing concepts. This resource contains 150 verified
questions and answers, each accompanied by detailed rationales that explain the correct answer and distractors,
promoting deep understanding and critical thinking. The content is organized into key areas including advanced
pathophysiology, pharmacotherapeutics, health assessment, evidence-based practice, leadership, and ethics.
Updated to reflect the latest guidelines and research, this document ensures students are well-prepared for the
exam and for clinical application. The answer format emphasizes clinical reasoning and decision-making, with
explanations that link theory to practice. This study guide is an essential tool for achieving a high score and
mastering the competencies required for advanced nursing practice.
Keywords:
NU 578, Unit 4 Exam, University of South Alabama, Advanced Nursing, Verified Questions, 2026/2027, Exam
Prep, A+ Guide
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale that explains why the answer is
correct and why the other options are incorrect. Distractors are analyzed to highlight common misconceptions and
clinical reasoning errors. This format reinforces learning and prepares students for similar questions on the exam.
Compliance Checklist:
All questions verified against 2026/2027 curriculum
Rationales align with current evidence-based practice
Page 1
, Content covers all Unit 4 learning objectives
Answers graded A+ by subject matter experts
Updated per latest University of South Alabama guidelines
Includes 150 unique, non-repetitive questions
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pathophysiology 1-35 Cellular adaptation, inflammation, 23%
hemodynamic disorders, neoplasia, genetic
disorders
Pharmacotherapeutics 36-70 Pharmacokinetics, pharmacodynamics, 23%
adverse effects, drug interactions, special
populations
Health Assessment & Diagnostic 71-100 Comprehensive history, physical exam 20%
Reasoning techniques, diagnostic tests, clinical
decision-making
Evidence-Based Practice & 101-120 Research designs, critical appraisal, EBP 13%
Research models, quality improvement, statistics
Leadership & Interprofessional 121-135 Team dynamics, conflict resolution, 10%
Collaboration delegation, healthcare policy, systems
thinking
Ethical & Legal Considerations 136-150 Informed consent, confidentiality, advance 10%
directives, malpractice, ethical principles
Page 2
,Q1. A patient with severe hepatic impairment (Child-Pugh class C) requires anticoagulation for recurrent
deep vein thrombosis. Which of the following anticoagulants is most appropriate, considering the need for
minimal hepatic metabolism and reversibility?
A. Warfarin, with close INR monitoring and dose adjustment based on hepatic function
B. Enoxaparin, dosed per actual body weight with anti-Xa monitoring
C. Apixaban, at a reduced dose of 2.5 mg twice daily
D. Edoxaban, at a standard dose of 60 mg once daily
Correct Answer: B. Enoxaparin, dosed per actual body weight with anti-Xa monitoring
Rationale: Enoxaparin is a low-molecular-weight heparin that undergoes minimal hepatic metabolism and is
primarily renally cleared. It has a predictable anticoagulant effect and can be monitored with anti-Xa levels if
needed. Warfarin is hepatically metabolized and its effect is highly variable in hepatic impairment. Apixaban and
edoxaban are direct oral anticoagulants (DOACs) that rely on hepatic metabolism via CYP3A4 and P-glycoprotein,
and are contraindicated in severe hepatic impairment due to increased bleeding risk.
Why Wrong:
A - Warfarin is hepatically metabolized and its anticoagulant effect is unpredictable in severe hepatic
impairment, increasing bleeding risk.
C - Apixaban is contraindicated in severe hepatic impairment due to its reliance on hepatic metabolism, and
dose reduction does not mitigate this risk.
D - Edoxaban is also contraindicated in severe hepatic impairment; its metabolism and excretion involve the
liver, and the standard dose is unsafe.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; American College of Chest
Physicians Guidelines for Antithrombotic Therapy, 2024.
Q2. Which of the following pharmacodynamic principles best explains why a patient with chronic opioid use
requires escalating doses to achieve the same analgesic effect?
A. Metabolic tolerance due to induction of hepatic CYP3A4 enzymes
B. Pharmacodynamic tolerance due to downregulation of mu-opioid receptors
C. Pharmacokinetic tolerance due to increased renal clearance of the opioid
D. Tachyphylaxis due to rapid desensitization of opioid receptors after each dose
Correct Answer: B. Pharmacodynamic tolerance due to downregulation of mu-opioid receptors
Rationale: Pharmacodynamic tolerance occurs with chronic opioid exposure as the body adapts by downregulating
mu-opioid receptors and uncoupling receptor-effector systems, requiring higher doses to achieve the same effect.
Metabolic tolerance (A) involves increased drug metabolism, which can contribute but is not the primary
mechanism. Pharmacokinetic tolerance (C) is a misnomer; increased clearance is not typical for opioids.
Tachyphylaxis (D) refers to rapid, acute tolerance after repeated doses over a short period, not the gradual
tolerance seen in chronic use.
Why Wrong:
A - Metabolic tolerance can occur but is secondary; the primary mechanism is receptor-level adaptation.
C - Renal clearance of opioids is generally unchanged with chronic use; tolerance is not due to increased
elimination.
D - Tachyphylaxis applies to rapid, short-term desensitization, not the gradual tolerance from chronic use.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 12; Brunton, L.L., et al. (2025).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed.
Q3. A patient with type 2 diabetes and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) is
currently on metformin 1000 mg twice daily and liraglutide 1.2 mg daily. HbA1c is 8.5%. Which of the
following medication adjustments is most appropriate based on current guidelines?
A. Discontinue metformin and add insulin glargine 10 units daily
B. Continue metformin but reduce dose to 500 mg twice daily and add dapagliflozin
Page 3
, C. Discontinue liraglutide and add sitagliptin 100 mg daily
D. Continue metformin at current dose and add pioglitazone 30 mg daily
Correct Answer: B. Continue metformin but reduce dose to 500 mg twice daily and add dapagliflozin
Rationale: In CKD stage 3b (eGFR 30-44), metformin should be used at a reduced dose (maximum 1000 mg/day) due to
increased risk of lactic acidosis. Dapagliflozin is an SGLT2 inhibitor that has shown renal and cardiovascular benefits in CKD
and can be started down to eGFR 25 mL/min/1.73m² per recent guidelines. Option A would discontinue metformin
prematurely without maximizing other agents. Sitagliptin (C) is less effective for glycemic control and does not offer renal
protection. Pioglitazone (D) can cause fluid retention and is not preferred with CKD.
Why Wrong:
A - Discontinuing metformin is not necessary; dose reduction is appropriate. Adding insulin may be needed later but not
as first step.
C - Sitagliptin is renally dosed but has no renal protective effect and is less potent than liraglutide or SGLT2 inhibitors.
D - Pioglitazone is not recommended in CKD due to risk of heart failure exacerbation and lack of renal benefit.
Reference: American Diabetes Association Standards of Medical Care in Diabetes, 2026; KDIGO 2024 Clinical Practice
Guideline for Diabetes Management in CKD.
Q4. A patient with a history of recurrent Clostridioides difficile infection (rCDI) is being considered for fecal
microbiota transplantation (FMT). Which of the following statements accurately reflects current
recommendations regarding FMT?
A. FMT is contraindicated in patients with inflammatory bowel disease due to risk of exacerbation
B. FMT should be reserved for patients who have failed at least two standard antibiotic courses for rCDI
C. FMT is most effective when administered via colonoscopy with fresh stool from a universal donor
D. FMT is associated with a 90% cure rate after a single infusion, regardless of donor selection
Correct Answer: B. FMT should be reserved for patients who have failed at least two standard antibiotic
courses for rCDI
Rationale: Current guidelines recommend FMT for patients with rCDI after at least two recurrences despite
appropriate antibiotic therapy (e.g., vancomycin or fidaxomicin). FMT is not contraindicated in IBD but requires
caution (A is false). While fresh stool is effective, frozen and lyophilized preparations are also used; colonoscopy is
one route but not the only effective method (C is not entirely accurate). Cure rates are approximately 70-80% after
a single infusion, not 90% (D is overstated).
Why Wrong:
A - FMT can be used in IBD patients with rCDI, though IBD activity should be controlled; it is not an
absolute contraindication.
C - FMT is effective via various routes (capsules, enema, colonoscopy) and with processed stool; route and
donor type are not singularly definitive.
D - Cure rates after single FMT are typically 70-80%; 90% is an overestimate and may require multiple
infusions.
Reference: IDSA/SHEA Clinical Practice Guidelines for Clostridioides difficile Infection, 2024 Update; Kelly,
C.R., et al. (2025). Fecal Microbiota Transplantation: Current Evidence and Future Directions.
Q5. A patient with a history of hypertension and hyperlipidemia presents with acute onset of severe chest
pain. ECG shows ST-segment elevation in leads V1-V4. The patient is given aspirin, nitroglycerin, and
morphine. Which of the following antiplatelet agents should be administered next, and what is the primary
mechanism of action?
A. Clopidogrel 600 mg loading dose; irreversible P2Y12 receptor antagonist
B. Ticagrelor 180 mg loading dose; reversible P2Y12 receptor antagonist
C. Prasugrel 60 mg loading dose; irreversible P2Y12 receptor antagonist
D. Abciximab 0.25 mg/kg bolus; glycoprotein IIb/IIIa receptor inhibitor
Correct Answer: B. Ticagrelor 180 mg loading dose; reversible P2Y12 receptor antagonist
Page 4
Verified Questions
NU 578 Unit 4 Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide for NU 578 Unit 4 at the University of South Alabama
features 150 verified questions and answers, meticulously curated to align with the 2026/2027
academic curriculum. Designed to facilitate mastery of advanced nursing concepts, this resource
provides detailed rationales and evidence-based explanations for each question. Students can
confidently prepare for the exam with this A+ graded study aid, which covers all critical content areas
and reflects the latest practice standards.
Key Features:
Advanced Pathophysiology and Pharmacotherapeutics
Health Assessment and Diagnostic Reasoning
Evidence-Based Practice and Research Integration
Leadership and Interprofessional Collaboration
Ethical and Legal Considerations in Advanced Practice
Patient Safety and Quality Improvement
Updates for 2026:
- Updated to reflect 2026/2027 curriculum changes
- Incorporated latest evidence-based practice guidelines
- Revised rationales for enhanced clarity and depth
- Added new questions on emerging healthcare topics
- Aligned with current NCLEX and advanced practice standards
Abstract:
The NU 578 Unit 4 Exam Prep Document for the 2026/2027 academic year at the University of South Alabama
offers a rigorous and comprehensive review of advanced nursing concepts. This resource contains 150 verified
questions and answers, each accompanied by detailed rationales that explain the correct answer and distractors,
promoting deep understanding and critical thinking. The content is organized into key areas including advanced
pathophysiology, pharmacotherapeutics, health assessment, evidence-based practice, leadership, and ethics.
Updated to reflect the latest guidelines and research, this document ensures students are well-prepared for the
exam and for clinical application. The answer format emphasizes clinical reasoning and decision-making, with
explanations that link theory to practice. This study guide is an essential tool for achieving a high score and
mastering the competencies required for advanced nursing practice.
Keywords:
NU 578, Unit 4 Exam, University of South Alabama, Advanced Nursing, Verified Questions, 2026/2027, Exam
Prep, A+ Guide
Answer Format:
Each question is followed by the correct answer and a comprehensive rationale that explains why the answer is
correct and why the other options are incorrect. Distractors are analyzed to highlight common misconceptions and
clinical reasoning errors. This format reinforces learning and prepares students for similar questions on the exam.
Compliance Checklist:
All questions verified against 2026/2027 curriculum
Rationales align with current evidence-based practice
Page 1
, Content covers all Unit 4 learning objectives
Answers graded A+ by subject matter experts
Updated per latest University of South Alabama guidelines
Includes 150 unique, non-repetitive questions
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Pathophysiology 1-35 Cellular adaptation, inflammation, 23%
hemodynamic disorders, neoplasia, genetic
disorders
Pharmacotherapeutics 36-70 Pharmacokinetics, pharmacodynamics, 23%
adverse effects, drug interactions, special
populations
Health Assessment & Diagnostic 71-100 Comprehensive history, physical exam 20%
Reasoning techniques, diagnostic tests, clinical
decision-making
Evidence-Based Practice & 101-120 Research designs, critical appraisal, EBP 13%
Research models, quality improvement, statistics
Leadership & Interprofessional 121-135 Team dynamics, conflict resolution, 10%
Collaboration delegation, healthcare policy, systems
thinking
Ethical & Legal Considerations 136-150 Informed consent, confidentiality, advance 10%
directives, malpractice, ethical principles
Page 2
,Q1. A patient with severe hepatic impairment (Child-Pugh class C) requires anticoagulation for recurrent
deep vein thrombosis. Which of the following anticoagulants is most appropriate, considering the need for
minimal hepatic metabolism and reversibility?
A. Warfarin, with close INR monitoring and dose adjustment based on hepatic function
B. Enoxaparin, dosed per actual body weight with anti-Xa monitoring
C. Apixaban, at a reduced dose of 2.5 mg twice daily
D. Edoxaban, at a standard dose of 60 mg once daily
Correct Answer: B. Enoxaparin, dosed per actual body weight with anti-Xa monitoring
Rationale: Enoxaparin is a low-molecular-weight heparin that undergoes minimal hepatic metabolism and is
primarily renally cleared. It has a predictable anticoagulant effect and can be monitored with anti-Xa levels if
needed. Warfarin is hepatically metabolized and its effect is highly variable in hepatic impairment. Apixaban and
edoxaban are direct oral anticoagulants (DOACs) that rely on hepatic metabolism via CYP3A4 and P-glycoprotein,
and are contraindicated in severe hepatic impairment due to increased bleeding risk.
Why Wrong:
A - Warfarin is hepatically metabolized and its anticoagulant effect is unpredictable in severe hepatic
impairment, increasing bleeding risk.
C - Apixaban is contraindicated in severe hepatic impairment due to its reliance on hepatic metabolism, and
dose reduction does not mitigate this risk.
D - Edoxaban is also contraindicated in severe hepatic impairment; its metabolism and excretion involve the
liver, and the standard dose is unsafe.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34; American College of Chest
Physicians Guidelines for Antithrombotic Therapy, 2024.
Q2. Which of the following pharmacodynamic principles best explains why a patient with chronic opioid use
requires escalating doses to achieve the same analgesic effect?
A. Metabolic tolerance due to induction of hepatic CYP3A4 enzymes
B. Pharmacodynamic tolerance due to downregulation of mu-opioid receptors
C. Pharmacokinetic tolerance due to increased renal clearance of the opioid
D. Tachyphylaxis due to rapid desensitization of opioid receptors after each dose
Correct Answer: B. Pharmacodynamic tolerance due to downregulation of mu-opioid receptors
Rationale: Pharmacodynamic tolerance occurs with chronic opioid exposure as the body adapts by downregulating
mu-opioid receptors and uncoupling receptor-effector systems, requiring higher doses to achieve the same effect.
Metabolic tolerance (A) involves increased drug metabolism, which can contribute but is not the primary
mechanism. Pharmacokinetic tolerance (C) is a misnomer; increased clearance is not typical for opioids.
Tachyphylaxis (D) refers to rapid, acute tolerance after repeated doses over a short period, not the gradual
tolerance seen in chronic use.
Why Wrong:
A - Metabolic tolerance can occur but is secondary; the primary mechanism is receptor-level adaptation.
C - Renal clearance of opioids is generally unchanged with chronic use; tolerance is not due to increased
elimination.
D - Tachyphylaxis applies to rapid, short-term desensitization, not the gradual tolerance from chronic use.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 12; Brunton, L.L., et al. (2025).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed.
Q3. A patient with type 2 diabetes and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) is
currently on metformin 1000 mg twice daily and liraglutide 1.2 mg daily. HbA1c is 8.5%. Which of the
following medication adjustments is most appropriate based on current guidelines?
A. Discontinue metformin and add insulin glargine 10 units daily
B. Continue metformin but reduce dose to 500 mg twice daily and add dapagliflozin
Page 3
, C. Discontinue liraglutide and add sitagliptin 100 mg daily
D. Continue metformin at current dose and add pioglitazone 30 mg daily
Correct Answer: B. Continue metformin but reduce dose to 500 mg twice daily and add dapagliflozin
Rationale: In CKD stage 3b (eGFR 30-44), metformin should be used at a reduced dose (maximum 1000 mg/day) due to
increased risk of lactic acidosis. Dapagliflozin is an SGLT2 inhibitor that has shown renal and cardiovascular benefits in CKD
and can be started down to eGFR 25 mL/min/1.73m² per recent guidelines. Option A would discontinue metformin
prematurely without maximizing other agents. Sitagliptin (C) is less effective for glycemic control and does not offer renal
protection. Pioglitazone (D) can cause fluid retention and is not preferred with CKD.
Why Wrong:
A - Discontinuing metformin is not necessary; dose reduction is appropriate. Adding insulin may be needed later but not
as first step.
C - Sitagliptin is renally dosed but has no renal protective effect and is less potent than liraglutide or SGLT2 inhibitors.
D - Pioglitazone is not recommended in CKD due to risk of heart failure exacerbation and lack of renal benefit.
Reference: American Diabetes Association Standards of Medical Care in Diabetes, 2026; KDIGO 2024 Clinical Practice
Guideline for Diabetes Management in CKD.
Q4. A patient with a history of recurrent Clostridioides difficile infection (rCDI) is being considered for fecal
microbiota transplantation (FMT). Which of the following statements accurately reflects current
recommendations regarding FMT?
A. FMT is contraindicated in patients with inflammatory bowel disease due to risk of exacerbation
B. FMT should be reserved for patients who have failed at least two standard antibiotic courses for rCDI
C. FMT is most effective when administered via colonoscopy with fresh stool from a universal donor
D. FMT is associated with a 90% cure rate after a single infusion, regardless of donor selection
Correct Answer: B. FMT should be reserved for patients who have failed at least two standard antibiotic
courses for rCDI
Rationale: Current guidelines recommend FMT for patients with rCDI after at least two recurrences despite
appropriate antibiotic therapy (e.g., vancomycin or fidaxomicin). FMT is not contraindicated in IBD but requires
caution (A is false). While fresh stool is effective, frozen and lyophilized preparations are also used; colonoscopy is
one route but not the only effective method (C is not entirely accurate). Cure rates are approximately 70-80% after
a single infusion, not 90% (D is overstated).
Why Wrong:
A - FMT can be used in IBD patients with rCDI, though IBD activity should be controlled; it is not an
absolute contraindication.
C - FMT is effective via various routes (capsules, enema, colonoscopy) and with processed stool; route and
donor type are not singularly definitive.
D - Cure rates after single FMT are typically 70-80%; 90% is an overestimate and may require multiple
infusions.
Reference: IDSA/SHEA Clinical Practice Guidelines for Clostridioides difficile Infection, 2024 Update; Kelly,
C.R., et al. (2025). Fecal Microbiota Transplantation: Current Evidence and Future Directions.
Q5. A patient with a history of hypertension and hyperlipidemia presents with acute onset of severe chest
pain. ECG shows ST-segment elevation in leads V1-V4. The patient is given aspirin, nitroglycerin, and
morphine. Which of the following antiplatelet agents should be administered next, and what is the primary
mechanism of action?
A. Clopidogrel 600 mg loading dose; irreversible P2Y12 receptor antagonist
B. Ticagrelor 180 mg loading dose; reversible P2Y12 receptor antagonist
C. Prasugrel 60 mg loading dose; irreversible P2Y12 receptor antagonist
D. Abciximab 0.25 mg/kg bolus; glycoprotein IIb/IIIa receptor inhibitor
Correct Answer: B. Ticagrelor 180 mg loading dose; reversible P2Y12 receptor antagonist
Page 4
